ImaBiotech S.A.S.. (3/29/16). "Press Release: ImaBiotech’s First Worldwide Patent Has Been Granted for Its Quantification Innovation in MSI". Lille.

	Region	United States (USA)
	Organisation	ImaBiotech S.A.S.
	Group	ImaBiotech (Group)
	Product	Quantinetix™ software for quantitative MALDI imaging
	Product 2	mass spectrometry imaging (MSI) (MALDI imaging)
	Person	Stauber, Jonathan (ImaBiotech 201206 CEO)
	Person 2	Fontaine, Edma (ImaBiotech 201512 Communication Manager)

First worldwide patent has been granted covering ImaBiotech’s research and services platform in the field of Mass Spectrometry Imaging (MSI).

ImaBiotech, a CRO company developing and offering new imaging technologies, applications and software, announces today that the company has been granted a patent in USA, France, Australia
and China for its lead innovation on quantitative MS Imaging (QMSI) and the development of the associated software, Multimaging.

Specifically, the QMSI patent covers the working method, the strategy, the method of validation, the
application, and the use of quantitative Mass Spectrometry Imaging including MALDI Imaging.

“This is a positive recognition of our hard work”, said Jonathan Stabuer, Chief Executive Officer of ImaBiotech. “The progress and recognition of our QMSI and MALDI Imaging services are now
supporting ImaBiotech’s growth and development of our US operations and facility. This patent coverage is critical for our ongoing efforts.”

About ImaBiotech

Located in Europe (France) and North America (Cambridge, MA), ImaBiotech (www.imabiotech.com) develops and offers services with new imaging technologies (Quantinetix™, Multimaging™) and applications. In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services to provide a cost-effective solution to preclinical and clinical studies. This molecular technique is used for qualitative & quantitative efficacy and toxicity of drug candidates from the whole body to cell levels.

Edma Fontaine,
ImaBiotech
Communication Manager
E: contact@imabiotech.com
T: +33 (0) 320 164 091

Record changed: 2016-03-30